Latest

psychopharmacology

·June 3, 2024·3 min read

Ozempic May Reduce Alcohol Abuse Risk

Diabetes drugs Wegovy and Ozempic, containing semaglutide, significantly reduce the incidence and recurrence of alcohol-use disorder (AUD). Analyzing health records, researchers observed a 50% to 56% decrease in AUD among patients treated with semaglutide.

Featured Neuroscience Psychology

·June 2, 2024·2 min read

Synthetic Estrogen in Birth Control Linked to Anxiety

Researchers suggest that the type of estrogen in hormonal birth control influences anxiety-like behaviors. Researchers found that synthetic estrogen in birth control led to increased anxiety behaviors in female rats compared to natural estrogen.

Featured Neuroscience

·May 31, 2024·3 min read

SSRIs Reveal New Potential Beyond Depression Treatment

A new study uncovers a key biological process targeted by SSRIs, suggesting new clinical applications. The study found that SSRIs affect membrane trafficking in cells, which might explain their broader effects. Remarkably, a single dose of fluvoxamine in mice enabled drug delivery across the blood-brain barrier. This discovery could lead to SSRIs aiding in the delivery of drugs for conditions like dementia.

Featured Neuroscience Psychology

·May 13, 2024·3 min read

Psilocybin Shows Promise in Anorexia Treatment

A new study highlights the potential of psilocybin, found in magic mushrooms, as a treatment for anorexia nervosa (AN), a psychiatric disorder with one of the highest mortality rates. The research demonstrated that psilocybin enhances cognitive flexibility and body weight maintenance in an animal model of AN.

Featured Neuroscience Psychology

·May 8, 2024·5 min read

Psychedelics Activate Serotonin to Produce Antidepressant Effect

A new study advanced our understanding of how psychedelic drugs activate serotonin receptors to offer potential treatments for neuropsychiatric disorders. The identifies the interaction of psychedelics like LSD and psilocybin with the serotonin receptor 5-HT1A, which is pivotal in their therapeutic effects.

Featured Neuroscience Psychology

·May 2, 2024·7 min read

Psilocybin Effective as Antidepressant

Psilocybin, the psychoactive compound in magic mushrooms, is notably more effective at alleviating depression symptoms than conventional controls. Analyzing seven trials with 436 participants, researchers found a substantial improvement in depression scores following psilocybin treatment compared to placebos or other minor psychedelic doses, showcasing a large effect size.

Featured Neurology Neuroscience Psychology

·April 20, 2024·7 min read

Risks of Antipsychotic Use in Dementia Patients

A new study revealed significant risks associated with antipsychotic use in dementia patients, including increased chances of stroke, heart failure, pneumonia, and other serious conditions. The research analyzed data from 173,910 dementia patients in England, tracking those prescribed antipsychotics post-diagnosis against those who were not.

Featured Neuroscience Psychology

·April 10, 2024·7 min read

Cannabis Compound Curbs Anxiety

A new study illuminated the anxiety-reducing potential of d-limonene, a natural component of cannabis, when combined with THC. The research showcases how vaporized d-limonene can mitigate the anxiety and paranoia often induced by THC, opening avenues for safer medicinal and recreational cannabis use.

Neuroscience

·March 12, 2024·6 min read

Mushroom Extract Outperforms Synthetic Psilocybin in Psychiatric Therapy

A new study reveals that psilocybin-containing mushroom extract exhibits a more potent and enduring effect on synaptic plasticity compared to its synthetic counterpart. This research highlights the potential of natural psychedelic compounds to revolutionize the treatment of psychiatric disorders. With alarming statistics indicating a significant portion of patients unresponsive to existing medications, this study opens new avenues for innovative, nature-based psychiatric treatments.

Featured Neuroscience Psychology

·February 23, 2024·4 min read

Ketamine’s Key to Unlocking Social Bonding in Depression

Researchers made a significant breakthrough in understanding how ketamine treats depression-related social impairments, focusing on the drug's effects in the mouse model. Their study shows that (R)-ketamine, as opposed to (S)-ketamine, effectively restores neuronal activity in the anterior insular cortex, a region crucial for emotional regulation and social cognition.

Featured Neuroscience Psychology

·February 16, 2024·3 min read

Antidepressants Impact Brain Development

Using antidepressants during pregnancy, specifically fluoxetine (found in Prozac and Sarafem), can significantly affect a child's brain development, particularly in the prefrontal cortex, potentially increasing the risk of mental health disorders later in life. The research highlights how serotonin, boosted by fluoxetine, directly impacts the development of synaptic connections in the prefrontal cortex, a critical area for high-order cognitive functions.

This shows a pink brain and a blue brain.

Featured Neuroscience Psychology

·February 12, 2024·7 min read

Ketamine’s Effects Diverge by Sex

Ketamine's effects on depression and pain, and its interaction with opioid pathways, significantly differ between sexes. In a detailed rat study, the team found that blocking opioid receptors nullified ketamine's impact only in males, suggesting a complex interplay between ketamine, opioid systems, and sex hormones.